Vaishali Pharma Share Price

Vaishali Pharma Limited, together with its subsidiaries, is a pharmaceutical company primarily engaged in the trading (including exports) and manufacturing of active pharmaceutical ingredients (APIs) and pharmaceutical formulations. The company operates through a single segment: Pharmaceuticals. It offers a wide range of products including APIs across various therapeutic categories such as anti-inflammatory, anti-diabetic, antifungal, vitamin, and veterinary products; formulation brands (tablets, capsules, injectables, liquids); surgical and casting tape products; herbal products; nutraceutical products; and oncology products. The company has manufactured and exported approximately 250 formulations and specializes in manufacturing tailor-made formulations.

The Vaishali Pharma share price today on the NSE and BSE is a reflection of how market participants respond to a company’s performance and broader business developments within its industry. It captures the sentiment of the investors based on financial results, operational updates, macroeconomic factors, and trends specific to sectors. Movements in the share price͏ reveal how the market evaluates the company’s current position and its future prospects, making ͏it a key indicator of market perception across various industries.

Market sentiment around the Vaishali Pharma stock price often mirrors shifts in generic drug demand, API pricing cycles, and investor views on the small-cap pharmaceutical sector’s growth prospects. Factors such as the pace of new product introductions, competitive intensity from domestic and international players, raw material cost inflation, and changing regulatory frameworks influence near-term market valuation and medium-term earnings forecasts.All these factors must be closely monitored to have an idea about the Vaishali Pharmastock price movements.

Vaishali Pharmalive share price provides real-time information about the last price traded, bid price, ask price, and volume traded. These indicators represent trading activity and liquidity and the reaction of investors to corporate announcements, quarterly results, and sector news. Constant ͏monitoring of Vaishali Pharmalive price helps observe short-term price fluctuations and understand how the stock is moving in relation to the broader market.

Furthermore, monitoring the Vaishali Pharmashare͏ price today helps investors understand real-time market sentiment, price volatility, and trading behaviour. It allows market participants to evaluate short-term performance, identifypossible entry or exit points, and respond to news, quarterly results or sector trends that may affect the company’s valuation and overall investment outlook.

Vaishali Pharma Limited Company Fundamentals

a. Company Background

Vaishali Pharma Limited is an Indian pharmaceutical company engaged in the trading and manufacturing of active pharmaceutical ingredients (APIs) and pharmaceutical formulations. The company traces its origins to 1989 when Vaishali Pharmachem, an API trading company, was founded. The company was originally incorporated as a private limited company under the name ‘Vaishali Pharma Private Limited‘ on April 25, 2008. On July 1, 2008, the company acquired the business of proprietorship concerns of its promoter Mr. Atul Vasani. The company was converted into a public limited company and changed its name to ‘Vaishali Pharma Limited‘. The company has its registered office in Mumbai, Maharashtra, India. Vaishali Pharma is a pharmaceutical bulk drug trading house that manufactures and exports various API ingredients and formulations. The company operates in domestic and export markets, with a presence in countries across Africa, Asia, and the Middle East. Vaishali Pharma completed its Initial Public Offering (IPO) on the NSE SME platform in August 2017, raising approximately ₹14.23 crore. The company operates within India‘s growing pharmaceutical industry, driven by rising healthcare demand, generic drug consumption, and export opportunities.

b. Product Lines

• Active Pharmaceutical Ingredients (APIs) across various therapeutic categories including anti-inflammatory, anti-diabetic, antifungal, vitamin, veterinary, anti-ulcer, anti-asthmatic, anti-viral, anti-psychotic, and cardiac

• Pharmaceutical formulations (tablets, capsules, injectables, liquids, creams, ointments)

• Surgical products (disposable surgical and casting tape products)

• Herbal products

• Nutraceutical products

• Oncology products

• Veterinary pharmaceutical products and supplements

• Formulation brands (approximately 250 formulations exported)

c. Company Revenue Model

• Primary revenue from the trading and export of active pharmaceutical ingredients (APIs) to domestic and international customers

• Revenue from the sale of pharmaceutical formulations across various therapeutic categories

• Revenue from the sale of surgical products, herbal products, nutraceuticals, and oncology products

• Revenue from exports of pharmaceutical products to international markets across Africa, Asia, and the Middle East

• Income from manufacturing of tailor-made formulations for specific client requirements

• Revenue from contract manufacturing and third-party manufacturing arrangements at over 22 different manufacturing sites

• Revenue from domestic distribution through pharmaceutical trade channels

d. Geographic Presence

• Registered office located in Mumbai, Maharashtra, India

• Manufacturing operations primarily conducted through third-party manufacturing arrangements at over 22 different sites, as the company does not own its manufacturing units

• Strong domestic presence serving pharmaceutical customers across India

• International presence through exports to Africa, Asia, and the Middle East

• Established office at Ho Chi Minh City, Vietnam for international operations

• Focus on expanding international footprint through API and formulation exports

• Delivery model leverages third-party manufacturing partnerships and global distribution channels

e. Key Milestones

• 1989: Inception of Vaishali Pharmachem, an API trading company

• 1994: Vaishali Pharmachem entered into joint venture with API manufacturing company Arochem Industries

• 2008: Incorporated as Vaishali Pharma Private Limited on April 25, 2008

• 2008: Acquired business of proprietorship concerns of promoter Mr. Atul Vasani on July 1, 2008

• 2017: Initial Public Offering (IPO) opened on August 7, 2017, and closed on August 10, 2017

• 2017: Shares listed on NSE SME platform on August 22, 2017 at issue price of ₹72 per share

• 2025: Announced debut acquisition of 51% majority stake in Kesar Pharma, marking first acquisition

f. Industry Perspective: Pharmaceutical Industry in India

Vaishali Pharma operates in the global and Indian pharmaceutical industry. Globally, the pharmaceutical market continues to expand driven by ageing populations, rising chronic disease prevalence, and healthcare innovation. In India, the pharmaceutical industry is one of the largest and fastest-growing sectors. The India Pharmaceutical Market size is estimated at USD 66.66 billion in 2025, and is expected to reach USD 88.86 billion by 2030, at a CAGR of 5.92% during the forecast period (2025-2030). According to IBEF, the Indian Pharmaceutical market stood at ₹4,71,295 crore (US$ 55 billion) in 2025 and is expected to grow to ₹10,28,280-11,13,970 crore (US$ 120-130 billion) by 2030. India‘s domestic pharmaceutical market is currently estimated at around $60 billion and is expected to double to about $130 billion by 2030. India’s pharma exports crossed $30 billion in FY25. India ranks as the third-largest pharmaceutical producer globally by volume and 14th by value, supplying over 50% of global vaccine demand and 40% of generic drugs to the US market. Key growth drivers include rising healthcare expenditure, increasing penetration of health insurance, government initiatives such as the National Health Mission and Ayushman Bharat, the production-linked incentive (PLI) scheme for pharmaceuticals, and the shift towards chronic therapies. The industry faces challenges including price regulation under the National Pharmaceutical Pricing Authority, intense competition, raw material dependency on China (API imports at 60-70%), and patent expiry pressures. However, the industry outlook remains positive, supported by strong domestic demand, export growth, and increasing healthcare awareness.

Vaishali Pharma Limited Stock Market Presence: Listings & Index Representation

Vaishali Pharma Limited is actively traded on India‘s principal equity markets, with its shares listed on the National Stock Exchange of India (NSE) under the symbol VAISHALI and on the Bombay Stock Exchange (BSE) with the scrip code 535000. The ISIN number of the company’s equity shares is INE972X01022. The face value of the equity shares is ₹10 per share. Its listing on both exchanges ensures that the Vaishali Pharma price is accessible to a wide investor base, encompassing both retail and institutional market participants. The company was listed on the NSE SME platform on August 22, 2017, following its IPO. The company forms part of several benchmark indices that represent broad market segments. Vaishali Pharma is included in indices such as the BSE SmallCap and Nifty Microcap 250. These index participations signal the company‘s relevance within market categories that attract both active and passive investment flows. Being represented in these indices enhances the visibility and liquidity of the Vaishali Pharma stock price, as index tracking funds and exchange traded strategies often adjust allocations in line with constituent revisions. It also allows investors to benchmark the company’s stock performance relative to broader market trends and peer groups, facilitating cross sectional comparisons within India‘s pharmaceutical landscape. The inclusion of Vaishali Pharma in these indices reflects its market capitalisation and trading depth, which are key factors market participants consider when evaluating long term investment prospects and the responsiveness of the stock price to corporate and industry developments.

Vaishali Pharma Limited Stock Performance and Share Price History

The Vaishali Pharma price has displayed extreme volatility since its listing on the NSE SME platform in August 2017, shaped by the company‘s financial performance, pharmaceutical sector cycles, and broader market trends. The Vaishali Pharma share price reached a 52-week high of ₹15.24 and a 52-week low of ₹4.75, indicating an extremely wide trading range and substantial price fluctuations. The Vaishali Pharma share price has decreased by approximately 48.36% over the last one year, significantly underperforming the broader market. The Vaishali Pharma share price has delivered a 3-year return of approximately -27.47%, indicating long-term wealth erosion for investors who held the stock over this period. The Vaishali Pharma share price delivered a 1-year return of approximately -51.13%, underperforming the Indian Pharmaceuticals sector which returned -6.4% over the same period. The Vaishali Pharma share price has also underperformed the Indian Market which returned 12.6% over the past year. As of April 2026, the Vaishali Pharma share price was trading at approximately ₹6.00-₹8.00 on the NSE, with a market capitalisation of approximately ₹80-₹90 crore.

The Vaishali Pharma stock price has been particularly responsive to quarterly earnings releases and corporate announcements. When the company reported a 25.85% year-on-year rise in net profit in certain quarters, the Vaishali Pharma stock price showed a positive reaction. However, when the company reported a net loss of ₹5.09 crore TTM as of March 2025, with a negative profit margin of -0.45%, the Vaishali Pharma stock price showed a negative reaction. The Vaishali Pharma price has shown a pattern of strong positive momentum following announcements of new export orders or acquisition news, while periods of weak financial results have contributed to consolidation in the Vaishali Pharma stock price. The Vaishali Pharma share price has been influenced by corporate developments including the company‘s debut acquisition of a 51% stake in Kesar Pharma in February 2025, and the expansion of its international footprint. The Vaishali Pharma share price has shown average weekly volatility of approximately 9.4%, which is higher than 75% of Indian stocks. The Vaishali Pharma share price has shown a weekly volatility of 9% over the past year, which has remained stable but is elevated compared to the broader market. The Vaishali Pharma share price has a beta coefficient that varies across different sources. Based on data, the beta for Vaishali Pharma has been recorded at 0.94 (medium volatility), while other sources report a beta of -0.0179, indicating negative correlation with market movements. The Vaishali Pharma share price has a debt-to-equity ratio higher than the industry average at 0.19 times. The Vaishali Pharma share price has a P/B ratio of 1.14 times as of April 2026, a 63% discount to its peers‘ median range of 3.10 times. The Vaishali Pharma share price has also shown a 10-year return that has been volatile, with the company‘s financial track record indicating average quality. Comprehending these patterns in the Vaishali Pharma share price is instrumental for investors seeking to contextualise long term performance trends vis à vis short term price dynamics, as the Vaishali Pharma stock price movements illustrate how industry fundamentals, API pricing cycles, regulatory changes, and investor expectations converge in market pricing.

Vaishali Pharma Limited Investor Relevance and Role in Portfolio

Vaishali Pharma holds a challenging position for portfolio investors who seek exposure to the Indian pharmaceutical sector with a focus on API trading and formulation exports. The company‘s diversified product portfolio across APIs, formulations, surgical products, herbal products, nutraceuticals, and oncology products aligns it with investment strategies that value both domestic pharmaceutical consumption and global generic drug demand. The Vaishali Pharma share price often mirrors how these themes resonate with investor portfolios, though the company‘s thin profitability and reliance on third-party manufacturing significantly limit institutional interest.

Institutional stakeholders play a minimal role in Vaishali Pharma‘s ownership profile. The promoters held approximately 31.61% of the company as of December 2025, showing an increase from 26.32% in previous quarters. The promoters are Atul Vasani and Jagruti Vasani. Mutual funds do not hold any stake in the company as of December 2025. Foreign Institutional Investors (FIIs) hold 0.00% of the company. Domestic Institutional Investors (DIIs) hold 0.00% of the company. Retail and other shareholders hold approximately 68.39% of the company. Overall institutional holding in the company stands at approximately 0.00% as of December 2025. The company‘s promoters have not pledged any significant portion of their shares.

Based on data, the beta for Vaishali Pharma has been recorded at 0.94, indicating that the stock has exhibited medium volatility compared to the broader market. Other sources report a beta of -0.0179, suggesting negative correlation with market movements. The Vaishali Pharma share price has shown periods of heightened responsiveness to sector-specific news, quarterly earnings releases, and raw material price movements. The Vaishali Pharma share price reflects that the company‘s position in the small-cap pharmaceutical sector may result in moderate to high price fluctuations. The Vaishali Pharma stock price is thus viewed as a speculative opportunity within a portfolio context with varying volatility characteristics depending on the time frame.

Vaishali Pharma Limited Sectoral Relevance and Peer Positioning

The sector relevance of Vaishali Pharma is anchored in its role within the broader Indian pharmaceutical industry, where it competes with other diversified API and formulation companies. As part of this industry, the company‘s strategic positioning connects active pharmaceutical ingredients (APIs), pharmaceutical formulations, surgical products, and nutraceuticals that serve multiple therapeutic segments. Competitors in adjacent segments include companies such as Sun Pharmaceutical Industries Limited, Divis Laboratories Limited, Torrent Pharmaceuticals Limited, Cipla Limited, Aarti Drugs Limited, and Gufic Biosciences Limited. Larger players such as Sun Pharma and Divis Labs have larger scale and diversified product portfolios, though Vaishali Pharma competes directly in the API trading and formulation export segment. Firms with parallels in either API portfolio or export relationships are often referenced when evaluating relative performance and operational positioning within the sector.

In valuation terms, factors like the Vaishali Pharma P/E ratio are not meaningful due to the company‘s negative earnings. The Vaishali Pharma P/E ratio has been negative or not available in recent periods, with values ranging from -158.14 to -274.64. The P/B ratio of Vaishali Pharma is 1.14 times as of April 2026, a 63% discount to its peers’ median range of 3.10 times. The Vaishali Pharma earnings history over the past five years has shown a pattern of extreme volatility. Annual revenue increased by 15.76% to ₹102.23 crore in FY2025 from ₹88.31 crore in FY2024. Net profit increased by 13.70% to ₹0.82 crore in FY2025 from ₹0.72 crore in FY2024. For TTM ended March 2025, net income stood at -₹5.09 million, with a negative profit margin of -0.45%. Quarterly revenue growth year-on-year was -11.70%. The Vaishali Pharma EPS narrative has followed a similar pattern of volatility. EPS (TTM) has been recorded at approximately -₹0.0452 to -₹0.05 over different periods. The Vaishali Pharma market cap has shown a pattern of significant contraction over the past decade. Vaishali Pharma market cap decreased from approximately ₹200 crore in earlier years to approximately ₹80-₹90 crore as of April 2026.

Over the last ten years, Vaishali Pharma market cap has shown a pattern of significant contraction. The company‘s market cap decreased from approximately ₹200 crore in earlier years to approximately ₹80-₹90 crore as of April 2026. The current market cap stands at approximately ₹80.50 crore, having ranged between lower levels and its current value over the past decade since IPO.

Vaishali Pharma earnings, in terms of net profit, have exhibited a pattern of extreme volatility over the past decade. Net profit increased from ₹0.72 crore in FY2024 to ₹0.82 crore in FY2025, up 13.70% year-on-year. For TTM ended March 2025, net income stood at -₹5.09 million. Quarterly net profit for the December 2025 quarter stood at ₹1.32 crore, down 8.33% year-on-year but up 10.92% quarter-on-quarter. Total revenue for H1 FY26 was ₹5,719.34 lakhs, up from ₹3,886.55 lakhs in H1 FY25.

Vaishali Pharma EPS history over the past decade has shown a pattern of negative values. EPS (TTM) has been recorded at approximately -₹0.0452 to -₹0.05 over different periods, with a current TTM EPS of approximately -₹0.0452. Basic EPS has ranged from negative to positive values over the past five years, reflecting the company‘s inconsistent profitability.

Vaishali Pharma P/E ratio history has been defined by not meaningful values due to negative earnings. For most years when the company reported losses, the P/E ratio was negative or not available. The P/E ratio stood at -158.14 to -274.64 in recent periods. The P/E ratio is not considered a meaningful valuation metric for the company at this time due to its inconsistent and negative earnings performance.

Summary

Vaishali Pharma is a small-cap Indian pharmaceutical company listed on the NSE, where the Vaishali Pharma share price reflects API pricing cycles, export demand trends, and competitive dynamics within the pharmaceutical sector. Its representation in stock indices supports market visibility, while investor interest is heavily constrained by thin profitability, negative earnings, and minimal institutional holding. Within the sector, the company‘s competitive context and earnings dynamics provide key perspectives on its role in the Indian API trading market.